References
- Pedersen, S. H. and Jeune, B. (1988). Prevalence of hormone replacement therapy in a sample of middle-aged women. Maturitas, 9(4), 339–345.
- Ringa, V., Ledésert, B. and Breart, G. (1994). Determinants of hormone replacement therapy among postmenopausal women enrolled in the French GAZEL cohort. Osteopor. Int., 4, 16–20.
- Chetkowski, F. J., Meldrun, D. R., Steingold, K. A., Randle, D., Lu, J. K., Eggena, P., Hershman, J. M., Alkjaersig, N. K., Fletcher, A. P. and Judd, H. L. (1986). Biological effects of transdermal estradiol. N. Engl. J. Med., 314, 1615–1620.
- Utian, W. H. (1987). Transdermal estradiol overall safety profile. Am. J. Obstet. Gynecol., 156, 1335–1338.
- Padwick, M. L., Endacott, J. and Whitehead, M. I. (1985). Efficacy, acceptability, and metabolic effects of transdermal estradiol in the management of postmenopausal women. Am. J. Obstet. Gynecol., 152, 1085–1091.
- Hillard, T. C., Whitcroft, S. J., Marsh, M. S., Ellerington, M. C., Lees, B., Whitehead, M. I. and Stevenson, J. C. (1994). Long term effect of transdermal and oral hormone replacement therapy on postmenopausal bone loss. Osteopor. Int., 4, 341–348.
- Crook, D. (1997). The metabolic consequences of treating postmenopausal women with non-oral hormone replacement therapy. Br J. Obstet. Gynaecol., 104 (Suppl 16), 4–13.
- Jensen, J. and Christiansen, C. (1988). Effects of smoking on serum lipoproteins and bone mineral contents during postmeno-pausal hormone replacement therapy. Am. J. Obstet. Gynecol., 159, 820–825.
- Hirvonen, E., Cacciatore, B., Wahlstrom, T., Rita, H. and Wilen-Rosenqvist, G. (1997). Effects of transdermal oestrogen therapy in postmenopausal women: a comparative study of an oestradiol gel and an oestradiol delivering patch. Br. J. Obstet. Gynaecol., 104 (Suppl 16), Nov. 26–31.
- Place, V. A., Powers, M., Darley, P. E., Schenkel, L. and Good, W. R. (1985). A double-blind comparative study of Estraderm and Premarin in the amelioration of postmenopausal symptoms. Am. J. Obstet. Gynecol., 152, 1092–1099.
- Frenkel, Y., Kopernik, G., Lazer, S., Tugendreich, D., Zmira, N., Oettinger, M., Tendler, R. and Serr, D. M. (1994). Acceptability and skin reactions to trans-dermal estrogen replacement therapy in relation to climate. Maturitas, 20, 31–36.
- Schneider, H. P. G. (1999). HRT and cancer risk: separating facts from fiction. Maturitas, 33, S65–S72.
- Rozenbaum, H., Birkhduser, M., De Nooyer, C., Lambotte, R., Pornel, B., Schneider, H. and Studd, J. (1996). Comparison of two estradiol transdermal systems (Oesclim® 50 and Estraderm® 50). I. Tolerability, adhesion and efficacy. Maturitas, 25, 161–173.
- Rozenbaum, H., Birkhduser, M., De Nooyer, C., Lambotte, R., Pornel, B., Schneider, H., Studd, J. and Thebault, J. (1996). Comparison of two estradiol transdermal systems (Oesclim® 50 and Estraderm® 50). II. Local skin tolerability. Maturitas, 25, 175–185.
- Utian, W. H., Burry, K. A., Archer, D. F., Gallagher, J. C., the Esclim Study Group, Boyett, R. L., Guy, M. P., Tachon, G. J., Chadha-Boreham, H. K. and Bouvet, A. A. (1999). Efficacy and safety of low, standard, and high dosages of an estradiol transdermal system (Esclim) compared with placebo on vasomotor symptoms in highly symptomatic menopausal patients. Am. J. Obstet. Gynecol. 181(1), July, 71–79.
- Newcombe, R. G. (1998). Two-sided confidence intervals for the single proportion: comparison of seven methods. Stats. Med., 17, 857–872.
- Stevenson, J. C. (1996). A-t-on besoin de différentes formes galéniques d'estrogènes et de progestatifs. In European Menopause Society, Conference de consensus, Montreux, Suisse. Birkhduser, M. H. and Rozenbaum H (Eds), Editions ESKA, Paris, p. 231.
- Stevenson, J. C. (1999). Risks and benefits of hormone replacement therapy. PL9, Climacteric, 2 (Suppl 1), Oct., 8.
- van de Weijer, P. H. M., van de Mooren, M. J., Barentsen, R. and Kenemans, P. (1999). The influence of the estradiol dose on bleeding patterns when combined in a sequential oral formulation with dydrogesterone. F084, Climacteric, 2 (Suppl 1), Oct., 115.
- Stevenson, J. C., Lees, B., Collins, S. and de Jonge, S. (1999). Low-dose HRT prevents postmenopausal osteoporosis in older women. F101, Climacteric, 2 (Suppl 1), Oct., 124.
- Bjarnasson, N. H., Byrjalsen, I., Hassager, C., Haarbo, J. and Christiansen, C. (1999). Low-dose estradiol in combination with gestodene is fully preventive in early postmenopausal women. P122, Climacteric, 2 (Suppl 1), Oct., 208.
- Ettinger, B., Pressman, A. and Vangessel, A. (1999). Tolerance and safety of low-dosage esterified estrogens combined with 6-monthly progestin. P126, Climacteric, 2 (Suppl 1), Oct., 210.